

More is more in pulmonary metastasectomy?

Benoît Bédat¹, Michel Gonzalez²

¹Service of Thoracic and Endocrine Surgery, University Hospitals of Geneva, Geneva, Switzerland; ²Service of Thoracic Surgery, Lausanne University Hospital (CHUV), Lausanne, Switzerland

Correspondence to: Benoît Bédat, MD. Service of Thoracic and Endocrine Surgery, Rue Gabrielle-Perret-Gentil 4, 1205 Genève, Switzerland. Email: Benoît.bedat@hcuge.ch.

Comment on: Prisciandaro E, Ceulemans LJ, Van Raemdonck DE, et al. Impact of the extent of lung resection on postoperative outcomes of pulmonary metastasectomy for colorectal cancer metastases: an exploratory systematic review. J Thorac Dis 2022;14:2677-88.

Submitted Sep 06, 2022. Accepted for publication Oct 21, 2022.

doi: 10.21037/jtd-22-1227

View this article at: https://dx.doi.org/10.21037/jtd-22-1227

Approximatively 20% of patients with colorectal cancer (CRC) will develop distant metastases with liver and lung being the most frequent sites (35% and 10%, respectively) (1). The management is generally palliative due to the frequent invasion of other organs. However, in selected patients, pulmonary metastases (PM) from CRC may be surgically managed with curative intent based on welldefined criteria: no distant metastases; lung metastases are resectable; patient can tolerate the surgery. This local aggressive approach is credited with a 5-year survival rate of >50%, thus could provide survival benefits for selected patients with lung metastases. Classically, the main goal of pulmonary metastasectomy is to achieve a complete resection of the metastases while preserving as much pulmonary parenchyma as possible. Thus, for peripheral lesions, resection is generally accomplished by wedge technique. This procedure can be repeated in the event of local recurrence. It is nowadays routinely performed by video-assisted thoracic surgery (VATS) to accelerate recovery and decrease post-operative complications, since this approach is associated with virtually no morbidity. This aspect is particularly relevant in metastatic patients, for whom quality of life is crucial. On the other hand, for central lesions, an anatomical resection (segmentectomy, lobectomy or pneumonectomy) may be necessary to ensure a complete resection. The recent European Society of Thoracic Surgeons (ESTS) database analysis reported that surgical resections were managed by wedge or local excision in 61% of cases and anatomical resection in 39% (lobectomy: 26%; segmentectomy: 11%; bilobectomy:

1%; pneumonectomy: 1%) (2). These recent results are quite similar to those reported in the international registry and published in 1997 (33% of anatomical resections). Generally, the extent of the resections for colorectal cancer metastases is mainly based on the number of lung metastases and their location. Yet, few reports have analysed the impact of the surgical extent on patient survival. In the Spanish prospective multicenter study, Hernández reported that anatomical resection was necessary in 19.9% of 522 patients (3). Interestingly, anatomical resection appeared to associated with a decreased HR for DSS [hazard ratio (HR) 0.6, 95% confidence interval (CI): 0.41–0.96, P=0.031] and DFS (HR 0.5, 95% CI: 0.36–0.75, P<0.001).

In the context of colorectal cancer pulmonary metastases, several elements may explain these results: the extent of the resection, the presence of spread through airways (STAS) and the importance of lymph node involvement.

In colorectal cancer patients, a major site of recurrence after wedge resection is the surgical margin, reported in 3.9% to 27.9% of cases (4,5). Welter *et al.* have demonstrated that in these patients, local recurrence rate after pulmonary metastasectomy was increased when the PM size was >5 mm and the safety margin <7 mm (6). In that sense, anatomical resection (by either segmentectomy or lobectomy) may potentially assure a better surgical margin than a wedge resection if deeply located metastases cannot be located during surgery or when the tumor is large. An attempt should be made to obtain a margin equal to or greater in length than the tumour size to minimize the risk of local recurrence (7).

Furthermore, STAS has been associated with an increased risk of local recurrence and is recognized as a poor prognostic factor (8,9). STAS, which is defined as the spread of cancer cells into air spaces in the lung parenchyma beyond the edge of the tumor, has been reported in up to 42% of PMs resulting from CRC. Considering the possibility of STAS in a significant number of cases, an extension of the surgical margin by anatomical resection should be proposed in case of large metastases.

The invasion of hilar or mediastinal lymph node involvement has been reported as an important prognostic factor of worse outcome (10). However, the impact of lymph node sampling/dissection in the context of pulmonary metastasectomy remains controversial. In a systematic review of the literature comprising 3,619 patients with colorectal pulmonary metastases, the five-year overall survival rate for all patients with lymph node metastases was 18.2% compared to 51.3% for patients without lymph node metastases (11). However, lymph node sampling or dissection is not a common surgical procedure in the management of PMs. Indeed, in international registry of lung metastases based on 5,206 patients reported in 1997 (12), lymph node sampling was performed in only 4.6% of patients. However, lymph node assessment was carried out in 58% of cases when a lobectomy was performed (2).

In this context, the systematic review proposed by Prisciandaro and colleagues is relevant. They performed a systematic review to assess the difference in short- and long-term outcomes depending on the surgical extent of pulmonary metastasectomy (13). Three retrospective studies were selected, including 1,342 patients. Unfortunately, a meta-analysis could not be carried out due to the major heterogeneity of the studies. For example, one study compared major resections (pneumonectomy and lobectomy) with lesser resections (wedge and segmentectomy), another study compared segmentectomy with wedge resection and the last one compared lobectomy with sub-lobar resection (segmentectomy and wedge). Not surprisingly, the extent of lung resection was influenced by the size of the metastases. However, none of these studies considered the location of the metastases (central vs. peripheral) to explain the extent of resection. In two studies, anatomical resections were protective factors for recurrence-free survival (RFS), and margin recurrences were more frequently observed in the wedge resection groups. However, the overall survival did not differ between patients who underwent anatomical resection or wedge resection. The lymph node assessment was also more

frequently performed in the anatomical resection groups.

Overall, the level of evidence of the selected studies remains low. Each of the three studies suffers from significant biases. The heterogeneity of the three studies does not allow a meta-analysis and the conclusion of this review should be considered cautiously. Certain studies may imply that lobectomies could be associated with better results, but we do not think that it can be a systematic conclusion. However, lobectomies could be performed in the event of central, large, or multiple metastases in the same lobe with acceptable results. It is important to perform the most conservative surgery in metastatic patients (14). A wedge resection by VATS seems to be the best procedure with low postoperative morbidity (5.2% of patients) (15). Furthermore, given the high risk of recurrence of this procedure (30%), it is important to perform a lung-sparing procedure (16).

This does not weaken in any way the methodological strength and reproducibility of the systematic review proposed by Prisciandaro and colleagues. This systematic review shows us the knowledge gap about pulmonary metastasectomy and the need to homogenize the variables of future studies.

Acknowledgments

We wish to thank Matthieu Zellweger, Ph.D. for his help and support.

Funding: None.

Footnote

Provenance and Peer Review: This article was commissioned by the editorial office, Journal of Thoracic Disease. The article did not undergo external peer review.

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://jtd.amegroups.com/article/view/10.21037/jtd-22-1227/coif). MG serves as an unpaid editorial board member of Journal of Thoracic Disease from February 2021 to January 2023. BB has no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Open Access Statement: This is an Open Access article

distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the noncommercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

References

- Pastorino U. Lung metastasectomy: why, when, how. Crit Rev Oncol Hematol 1997;26:137-45.
- Gonzalez M, Brunelli A, Szanto Z, et al. Report from the European Society of Thoracic Surgeons database 2019: current surgical practice and perioperative outcomes of pulmonary metastasectomy. Eur J Cardiothorac Surg 2021;59:996-1003.
- Hernández J, Molins L, Fibla JJ, et al. Role of major resection in pulmonary metastasectomy for colorectal cancer in the Spanish prospective multicenter study (GECMP-CCR). Ann Oncol 2016;27:850-5.
- Shiono S, Ishii G, Nagai K, et al. Predictive factors for local recurrence of resected colorectal lung metastases. Ann Thorac Surg 2005;80:1040-5.
- Higashiyama M, Kodama K, Takami K, et al.
 Intraoperative lavage cytologic analysis of surgical margins as a predictor of local recurrence in pulmonary metastasectomy. Arch Surg 2002;137:469-74.
- Welter S, Arfanis E, Christoph D, et al. Growth patterns of pulmonary metastases: should we adjust resection techniques to primary histology and size? Eur J Cardiothorac Surg 2017;52:39-46.
- 7. Nelson DB, Tayob N, Mitchell KG, et al. Surgical margins and risk of local recurrence after wedge resection

Cite this article as: Bédat B, Gonzalez M. More is more in pulmonary metastasectomy? J Thorac Dis 2022;14(12):4593-4595. doi: 10.21037/jtd-22-1227

- of colorectal pulmonary metastases. J Thorac Cardiovasc Surg 2019;157:1648-55.
- 8. Shiono S, Ishii G, Nagai K, et al. Histopathologic prognostic factors in resected colorectal lung metastases. Ann Thorac Surg 2005;79:278-83.
- Takeda-Miyata N, Konishi E, Tanaka T, et al. Prognostic significance of spread through air spaces in pulmonary metastases from colorectal cancer. Lung Cancer 2020;149:61-7.
- Zellweger M, Abdelnour-Berchtold E, Krueger T, et al. Surgical treatment of pulmonary metastasis in colorectal cancer patients: Current practice and results. Crit Rev Oncol Hematol 2018;127:105-16.
- 11. van Dorp M, Bousema JE, Torensma B, et al. Pulmonary metastasectomy with lymphadenectomy for colorectal pulmonary metastases: A systematic review. Eur J Surg Oncol 2022;48:253-60.
- 12. Pastorino U, Buyse M, Friedel G, et al. Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases. J Thorac Cardiovasc Surg 1997;113:37-49.
- 13. Prisciandaro E, Ceulemans LJ, Van Raemdonck DE, et al. Impact of the extent of lung resection on postoperative outcomes of pulmonary metastasectomy for colorectal cancer metastases: an exploratory systematic review. J Thorac Dis 2022;14:2677-88.
- 14. Perentes JY, Zellweger M, Gonzalez M. Personalized surgery for the management of pulmonary metastasis. J Thorac Dis 2018;10:52-5.
- Abdelnour-Berchtold E, Perentes JY, Ris HB, et al. Survival and Local Recurrence After Video-Assisted Thoracoscopic Lung Metastasectomy. World J Surg 2016;40:373-9.
- 16. Forster C, Ojanguren A, Perentes JY, et al. Is repeated pulmonary metastasectomy justified? Clin Exp Metastasis 2020;37:675-82.